220 related articles for article (PubMed ID: 25270772)
1. Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?
van der Wijst MG; Brown R; Rots MG
Biochim Biophys Acta; 2014 Dec; 1846(2):494-509. PubMed ID: 25270772
[TBL] [Abstract][Full Text] [Related]
2. Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.
van der Wijst MG; Huisman C; Mposhi A; Roelfes G; Rots MG
Mol Oncol; 2015 Aug; 9(7):1259-73. PubMed ID: 25841766
[TBL] [Abstract][Full Text] [Related]
3. Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.
Martinez VD; Vucic EA; Thu KL; Pikor LA; Hubaux R; Lam WL
Biomed Res Int; 2014; 2014():159459. PubMed ID: 25114896
[TBL] [Abstract][Full Text] [Related]
4. NRF2 in human neoplasm: Cancer biology and potential therapeutic target.
Liu Y; Lang F; Yang C
Pharmacol Ther; 2021 Jan; 217():107664. PubMed ID: 32810525
[TBL] [Abstract][Full Text] [Related]
5. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents.
Giudice A; Arra C; Turco MC
Methods Mol Biol; 2010; 647():37-74. PubMed ID: 20694660
[TBL] [Abstract][Full Text] [Related]
6. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
7. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
[TBL] [Abstract][Full Text] [Related]
8. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress and Cancer: The Role of Nrf2.
Sajadimajd S; Khazaei M
Curr Cancer Drug Targets; 2018; 18(6):538-557. PubMed ID: 28969555
[TBL] [Abstract][Full Text] [Related]
10. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.
Cucci MA; Grattarola M; Dianzani C; Damia G; Ricci F; Roetto A; Trotta F; Barrera G; Pizzimenti S
Free Radic Biol Med; 2020 Apr; 150():125-135. PubMed ID: 32101771
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
12. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
13. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
14. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Manandhar S; Choi BH; Jung KA; Ryoo IG; Song M; Kang SJ; Choi HG; Kim JA; Park PH; Kwak MK
Free Radic Biol Med; 2012 May; 52(9):1773-85. PubMed ID: 22387177
[TBL] [Abstract][Full Text] [Related]
15. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy.
Loignon M; Miao W; Hu L; Bier A; Bismar TA; Scrivens PJ; Mann K; Basik M; Bouchard A; Fiset PO; Batist Z; Batist G
Mol Cancer Ther; 2009 Aug; 8(8):2432-40. PubMed ID: 19638449
[TBL] [Abstract][Full Text] [Related]
16. NRF2 and p53: Januses in cancer?
Rotblat B; Melino G; Knight RA
Oncotarget; 2012 Nov; 3(11):1272-83. PubMed ID: 23174755
[TBL] [Abstract][Full Text] [Related]
17. A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue.
Bowman BM; Montgomery SA; Schrank TP; Simon JM; Ptacek TS; Tamir TY; Mulvaney KM; Weir SJ; Nguyen TT; Murphy RM; Makowski L; Hayes DN; Chen XL; Randell SH; Weissman BE; Major MB
J Pathol; 2020 Oct; 252(2):125-137. PubMed ID: 32619021
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant-induced INrf2 (Keap1) tyrosine 85 phosphorylation controls the nuclear export and degradation of the INrf2-Cul3-Rbx1 complex to allow normal Nrf2 activation and repression.
Kaspar JW; Niture SK; Jaiswal AK
J Cell Sci; 2012 Feb; 125(Pt 4):1027-38. PubMed ID: 22448038
[TBL] [Abstract][Full Text] [Related]
19. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
Dempke WCM; Reck M
Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Nrf2-an update.
Niture SK; Khatri R; Jaiswal AK
Free Radic Biol Med; 2014 Jan; 66():36-44. PubMed ID: 23434765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
